Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. [electronic resource]
Producer: 20130829Description: 2460-8 p. digitalISSN:- 1527-7755
- Adolescent
- Antineoplastic Agents -- administration & dosage
- Benzamides -- administration & dosage
- Child
- Child, Preschool
- Dasatinib
- Diarrhea -- chemically induced
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Headache -- chemically induced
- Humans
- Imatinib Mesylate
- Infant
- Kaplan-Meier Estimate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Nausea -- chemically induced
- Piperazines -- administration & dosage
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- administration & dosage
- Sample Size
- Therapies, Investigational
- Thiazoles -- administration & dosage
- Treatment Outcome
- Vomiting -- chemically induced
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.